TAES for FPVCs: a Pragmatic, Randomized Controlled Trial

Last updated: July 16, 2025
Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Overall Status: Active - Recruiting

Phase

N/A

Condition

Arrhythmia

Treatment

Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham-TAVNS)

Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS)

Clinical Study ID

NCT04415203
TAESforFPVC
  • Ages 18-75
  • All Genders

Study Summary

This prospective, randomized controlled trial aims to evaluate the efficacy and safety of Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS) for patients with frequent premature ventricular coomplexes (FPVCs). Ninety participants will be randomized to TAVNS group and sham-TAVNS group with the ratio of 1:1. They will receive TAVNS plus usual care or sham-TAVNS plus usual care for 6 weeks, and then be followed up for 12 weeks after the treatment. The primary outcome was the proportion of participants with a 50% decrease of the 24 hour (24h) premature ventricular complexes (PVCs) after 6-week treatment. Secondary outcomes include the proportion of participants with a 75% decrease of the 24h-PVCs; the decrease from baseline of 24h-PVCs, total 24h-heartbeat, and the frequency of supraventricular arrhythmia; the score change from baseline in PVCs-related symptoms; the score change from baseline in SAS and SDS. Subgroup analyses will be performed in age, gender, and the severity of PVCs. Safety assessment will be documented during the whole trial.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosed as frequent premature ventricular contractions;

  • 2 ≤ Lown level ≤ 4A;

  • 18 ≤ age ≤ 75;

  • Volunteered to participant

Exclusion

Exclusion Criteria:

  • Severe valvular disease, congenital heart disease, pericardial disease, hypertrophiccardiomyopathy, unstable angina pectoris, acute myocardial infarction, myocarditis,aneurysm, congestive heart failure decompensation period (NYHA grade III or VI),cardiogenic shock, cerebrovascular disease, hematopoietic system disease, severemental disease;

  • Bradycardia, including pathologic sinus node syndrome, degree II or greateratrioventricular block;

  • Those who have already had pacemaker or percutaneous coronary intervention, or whoplan to have pacemaker or percutaneous coronary intervention;

  • Pregnant or lactating women;

  • Local sensory deficit, or allergic to current;

  • May be allergic to percutaneous patches；

  • Blood pressure ≤ 90/60 mmHg;

  • Those who have participated in other clinical trials within 3 months.

Study Design

Total Participants: 90
Treatment Group(s): 2
Primary Treatment: Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham-TAVNS)
Phase:
Study Start date:
June 04, 2020
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Guang'anmen Hospita, China Academy of Chinese Medical Sciences

    Beijing, Beijing 100053
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.